Actinium Pharmaceuticals, Inc, also called Actinium Pharmaceuticals, is a clinical-stage biopharmaceutical company. It is focused on developing Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Read More The firm provides its service through Iomab-B, which is studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The company was founded in 2002 and is headquartered in New York, NY.